---

Market Overview

---

The Connected Drug Delivery Devices Market is projected to experience significant growth, with an expected increase from USD 869 million in 2023 to USD 3,916 million by 2028. This growth is attributed to the increasing prevalence of chronic diseases, such as asthma, COPD, and diabetes, as well as the rising geriatric population.

Connected drug delivery devices are wireless and smart electronic devices that enable patients to administer their own therapy. These devices are equipped with electronics and sensors that track dose delivery and timing, providing instant feedback to patients.

The COVID-19 pandemic had a moderate impact on the market initially, as patient care shifted to home-based technologies, leading to an increase in the usage of connected drug delivery devices. However, as the pandemic has subsided, the shift towards home-based care has decreased slightly. Nevertheless, the market is expected to maintain stable growth during the forecast period.

Key drivers of market growth include the increasing prevalence of chronic diseases, heightened patient connectivity and engagement, and growing patient awareness about the importance of adhering to prescribed therapies.

The high burden of chronic diseases such as asthma, COPD, and diabetes, along with the growing geriatric population, is expected to drive market growth. For example, it is estimated that 200 million people worldwide had COPD in 2022, and the prevalence of COPD in adults in India was 9.23% in the same year. The rising prevalence of diabetes is also a significant factor, with approximately 537 million adults aged 20-79 years living with diabetes in 2021, and this number projected to increase in the coming years.

Asthma is another common chronic disease, affecting a significant percentage of the population in countries like Germany. Additionally, the prevalence, awareness, and control rates of diabetes in Chinese individuals aged over 65 years were found to be notable. These high prevalence rates of asthma and diabetes further contribute to the usage of connected drug delivery devices, thereby driving market growth.

However, challenges such as the increased cost of devices and concerns about data privacy and transfer may impede market growth.

The Connected Drug Delivery Devices Market is expected to witness substantial growth, driven by factors such as the increasing prevalence of chronic diseases, the rising geriatric population, and the growing awareness of adherence to prescribed therapies. Despite challenges, the market is poised for expansion in the coming years.

---

Market Segmentation

---

The market is segmented based on various factors, including product, technology, end user, and geography.

Segmentation by Product
Connected Sensors – Connected Inhaler Sensors, Connectable Injection Sensors
Integrated Connected Devices – Connected Inhaler Devices, Connected Injection Devices

Segmentation by Technology
Bluetooth
Near-field communication (NFC)
Other Technologies

Segmentation by End User
Healthcare Providers
Homecare

Segmentation by Geography
North America – United States, Canada, Mexico
Europe – United Kingdom, Germany, France, Italy, Spain, and Rest of Europe
Asia-Pacific – China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific
Latin America – Brazil, Argentina, and Rest of Latin America
Middle East and Africa – GCC, South Africa, and Rest of Middle East and Africa

Integrated connected devices hold the largest share in the market, primarily due to technological advancements, increasing adoption of connected inhaler devices, product launches, and product approvals.

Among the technology segments, Bluetooth technology is believed to hold the largest share. This is attributed to its high availability in smartphones and ease of access. Bluetooth technology is a wireless connection that enables high-speed, low-energy communication between portable devices. It operates in the 2.45 GHz frequency band and can support up to 721 KBps and three voice channels. This technology allows medical devices to communicate wirelessly over short distances, typically up to 30 feet (10 meters). It is cost-effective and widely used in the industry.

In terms of end-users, the homecare segment is expected to hold the largest share. This is driven by the growing use of connected drug delivery devices at home and increasing adoption for home use. The segment is projected to experience significant growth due to the rising cases of cardiovascular diseases (CVDs), diabetes, chronic obstructive pulmonary disease (COPD), and other chronic diseases that require proper health record maintenance. Additionally, innovations in connected drug delivery devices are expected to further boost segment growth.

The increasing prevalence of diabetes, coupled with the rising geriatric population, is a major factor driving the growth of the homecare segment. Older individuals often require treatment at home, and the prevalence of diabetes is particularly high in this population. For instance, data from the International Diabetes Federation (IDF) shows that a significant portion of new type one diabetes cases in 2022 were in individuals aged 20 years or older. Similarly, the number of people living with diabetes is substantial in various regions globally, including Africa, Europe, the Middle East and North Africa, and South-East Asia.

Furthermore, cardiovascular diseases (CVDs) are widely prevalent and a leading cause of morbidity, disability, and mortality worldwide. The burden of CVDs and diabetes has been on the rise, contributing to excess deaths in England and Wales. This increase in chronic diseases globally is expected to drive the usage of connected drug delivery devices in home settings.

Geographically, North America holds the largest share in the market, with the United States being a significantly large market. The region experiences a high incidence rate of chronic diseases and has a substantial target population base. Asthma affects around 25 million people in the United States, and COPD affects over 15 million Americans annually. Additionally, Canada has a significant geriatric population, which is more prone to chronic diseases, further driving the demand for connected drug delivery devices.

---

Competitive Landscape

---

The connected drug delivery devices market exhibits a fragmented nature, with key market players engaging in strategic collaborations, acquisitions, and new product launches to maintain their competitive edge. Noteworthy participants in the connected drug delivery devices market include Propeller Health (ResMed Inc.), BioCorp, Findair Sp. z.o.o, and Adherium Limited, among others.

Key companies profiled in this report include Propeller Health (ResMed Inc.), Findair Sp. z o.o., Bio Corp, Teva Pharmaceuticals Industries Ltd, Adherium Limited, West Pharmaceutical Services Inc., Aptar Pharma, Ypsomed AG, Phillips-Medisize.

---

Recent Industry Developments

---

In May 2022, Jabil Healthcare, a division of Jabil Inc., introduced the Qfinity autoinjector platform in the United States. This platform is a reusable drug delivery device designed for subcutaneous (SC) drug self-administration. Additionally, the product is also available in a connected option.

In February 2022, Aptar Pharma, a renowned global provider of drug delivery systems, launched the HeroTracker Sense in the United States. This innovative solution is a digital respiratory health device that enhances a standard metered dose inhaler (pMDI) by transforming it into a smart connected healthcare device.

---

Key Questions Answered

---

What is the projected size of the Connected Drug Delivery Devices Market?
The Connected Drug Delivery Devices Market is expected to reach a size of USD 869 million in 2023 and is projected to grow at a CAGR of 35.13% to reach USD 3,916 million by 2028.

What is the current size of the Connected Drug Delivery Devices Market?
The Connected Drug Delivery Devices Market is expected to reach a size of USD 869 million in 2023.

Who are the major players in the Connected Drug Delivery Devices Market?
The major companies operating in the Connected Drug Delivery Devices Market include West Pharmaceutical Services, Inc., FindAir, Adherium Limited, BIOCORP, and Propeller Health (ResMed Inc.).

Which region is experiencing the highest growth in the Connected Drug Delivery Devices Market?
Asia Pacific is estimated to have the highest compound annual growth rate (CAGR) over the forecast period (2023-2028).

Which region has the largest market share in the Connected Drug Delivery Devices Market?
In 2023, North America holds the largest market share in the Connected Drug Delivery Devices Market.